We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Assura Plc | LSE:AGR | London | Ordinary Share | GB00BVGBWW93 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.10 | -0.25% | 40.56 | 6,388,964 | 16:29:58 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 40.56 | 40.62 | 40.68 | 40.44 | 40.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Real Estate Agents & Mgrs | 157.8M | -28.8M | -0.0089 | -45.57 | 1.32B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:38:53 | O | 5,688 | 40.56 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/10/2024 | 12:00 | UK RNS | Assura PLC Director/PDMR Shareholding |
| 08/10/2024 | 16:20 | UK RNS | Assura PLC Director/PDMR Shareholding |
| 07/10/2024 | 09:59 | ALNC |  Assura well positioned to facilitate UK healthcare structural change |
| 07/10/2024 | 07:00 | UK RNS | Assura PLC Scrip Dividend Declaration |
| 07/10/2024 | 07:00 | UK RNS | Assura PLC Trading Update |
| 23/9/2024 | 09:14 | UK RNS | Assura PLC Holding(s) in Company |
| 16/9/2024 | 16:30 | UK RNS | Assura PLC Holding(s) in Company |
| 12/9/2024 | 08:33 | UK RNS | Assura PLC Scrip Calculation Price |
| 09/9/2024 | 11:51 | ALNC | EXECUTIVE CHANGES: Revolution Bars confirms Luke Johnson as chair |
| 09/9/2024 | 10:42 | UK RNS | Assura PLC Director/PDMR Shareholding |
Assura (AGR) Share Charts1 Year Assura Chart |
|
1 Month Assura Chart |
Intraday Assura Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-11 15:38:53 | 40.56 | 5,688 | 2,307.05 | O |
| 2024-10-11 15:35:09 | 40.56 | 2,454 | 995.34 | AT |
| 2024-10-11 15:35:09 | 40.56 | 1,753,826 | 711,351.83 | UT |
| 2024-10-11 15:30:51 | 40.47 | 375,000 | 151,762.50 | O |
| 2024-10-11 15:30:51 | 40.47 | 375,000 | 151,779.71 | O |
| Top Posts |
|---|
Posted at 11/10/2024 09:20 by Assura Daily Update Assura Plc is listed in the Real Estate Agents & Mgrs sector of the London Stock Exchange with ticker AGR. The last closing price for Assura was 40.66p.Assura currently has 3,236,951,244 shares in issue. The market capitalisation of Assura is £1,312,907,425. Assura has a price to earnings ratio (PE ratio) of -45.57. This morning AGR shares opened at 40.50p |
Posted at 04/10/2024 13:47 by speedsgh Merchants Trust: Why we like ‘robust’ Assura Group - Simon Gergel of Merchants on why Assura, the real estate investment trust and GP landlord, is attractive on a 12% share price discount and 8% yield. |
Posted at 12/9/2024 17:42 by dandigirl Of course you are right, goliard. Just hope that the "Canadian" acquisition makes a difference to the top line.The company is flat lining at best. Last year was not a great year with, by the way, no debt repaid. However, there are a number of projects which should move to revenue generation later this year.We hold AGR, IHR, PHP and THRL. All have had a good 6 months, except AGR.One theme that seems to be coming through though is that the NHS are not a push over when it comes to new projects. I think I am right in that all of the above will not start new projects without agreement on rentals and that is not easily achieved. Hence, new projects, which take a long time to bring to fruition, are being moth-balled. |
Posted at 12/9/2024 12:06 by dandigirl Share price just not moving above the low 40s. Need to increase the dividends more than in the past. 0.02/0.04 increase just not enough. |
Posted at 11/9/2024 07:27 by goliard Weak growth figures today should mean a higher chance of interest rate cuts and that should mean a boost to AGR price... but let's see. |
Posted at 05/9/2024 09:54 by this_is_me AGR looks like better value than PHP at current share prices. I bought to hold long term for the dividend but, of course, that doesn't mean that I will not sell if the share price goes way up. |
Posted at 14/8/2024 21:11 by blueclyde Looking back at the results the NAV of Assura was nearly 50p a share vs a share price of 41p. So they issued new shares at a 20% discount to their intrinsic value to buy a company that was on a 12 percent discount to NAV. Just crazy. |
Posted at 30/6/2024 23:05 by kernelthread Unless I'm missing something, paying a dividend in scrip is equivalent to not paying a dividend at all. The total number of shares per se is irrelevant; all that matters is what proportion of the total equity in the company is owned by a particular shareholder. For example, if you doubled the total number of shares in the company but also doubled the holding of each shareholder (i.e. 2 to 1 share split), the share price would halve but the total value of everyone's holding stays constant, as does the dividend they receive (dividend per share halves, but they have twice as many shares). Paying a dividend in scrip increases each shareholder's holding by the same factor of F = (1 + y/100) where y is the yield in %. So each share is worth (1/F) times what it was before, but each holder has F times as many shares, so total value is the same. The share price can be expected to drop by a factor of F. Nobody receives any cash (except for some 'financial friction' in the form of brokers etc. paid to issue the RNSs and update records of how many shares in circulation and who owns them). |
Posted at 23/5/2024 12:37 by essentialinvestor Much better for the share price outlook to cut the divi by 15-20%.Once the market begins to question payout sustainability, the air hangs heavy over the share price like a dulling wine. |
Posted at 22/5/2024 09:44 by george stobart Jefferies Note - Wednesday, May 22, 2024FY24: Not Quite a Clean Bill of Health - PT 45p and cut to Hold LTV is 43% with the new JV, but more action is needed to allay the risk a credit cut. Options include an equity injection (shares trade at 13% disc to NAV), asset disposals (earnings dilutive by c. 300-400bps) and curtail development (AGR is being priced out). Our PT is cut to 45p factoring in the dilutive impact of £200m (Jef Est) pa high yield/low growth asset sales to degear to 30% but the 7.8% DY risks being uncovered (FY25 1x). The shares are cut to Hold. Earnings & Dividends: In FY24 net rents were +4% to £143.3m with average reviews +3.9% (FY23: 3.8%) governed by the district valuer, the commercial arm of the Valuation Office Agency which advises the NHS on valuations, rent reviews and rents on new developments. Vacancies are 1% (unch) and the contracted rent roll £150.6m pa, rising to an all up £161m on developments and reviews. Admin was £13.2m with an EPRA Cost Ratio (incl & excl vacancy costs) 13.2% and 11.7% resp. (FY23: 13.5% & 12.3%). EPS was flat at 3.4p (FY23: 3.3p) and +5% DPS 3.26p, below the 10yr CAGR of 7.3%. Portfolio Performance: Revalued at £2708m on NIY of +30bps to 5.17% after a -4% Lfl w/down (FY23 -6.4%) partly offset by value activity. The NAV was -8% to 49.4p but the spread wide at NIYs 3.8%-8.5% (equiv 3.9%-8.5% so there is thin organic growth) with the valuer's ERV assumptions £100-£750/sqm (FY23: £100-£669/sqm). The new 15yr life JV with USS diversifies funding and will be seeded with seven (no development, long dated, index linked) assets from AGR valued at £107m at an undisclosed discount. The JV will target acquisition-led growth to £250m with AGR retaining a 20% stake with a management fee. Development Programme: AGR does not disclose target returns and five schemes were completed with a value of £71.8m in a mix of GP surgeries and broader healthcare markets. Three new schemes are underway with two in Ireland and one in Bury St Edmunds, making eight schemes on site with a combined development cost of £91.2m with £42m remaining to spend. Higher construction and financing costs are affecting the pipeline as AGR needs c 30% higher rents to be viable and thus schemes are being postponed. Financial Position: Net debt is £1.2bn (all unsecured) at a kd of 2.3% (unch, all fixed) and termed 6yrs. Over the next four years, £170m of debt needs refinancing which at 5.5% would impact EPS by -6%. Gearing is, we maintain, too high and risks cut from Fitch A-. The net debt/EBITDA ratio at 9.4x is >9x Fitch’s rating sensitivity, and 4-5x looks more appropriate. The LTV at 45% is elevated after two years of portfolio w/downs and can operate in the range 40-50% but we view <40% as appropriate. The 3% 2028 bond (Ex 1 traded above its issue spread in 2023. Outlook: CEO Jonathan Murphy: "The long-term partnership aligns with cross-party political support for investment into essential NHS community healthcare buildings.” |
Posted at 02/5/2024 13:42 by goliard Unfiltered Blue but regretted it. However, just to help a little, you do realise that anyone purchasing 2.5% of a company would not just go into the market and hoover up all the shares? What they do is speak to other holders via brokers and agree to purchase from them at an agreed price. They do that exactly because it does not move the share price up and cause them to overpay. You also need to realise that whilst they bought 2.5% of the company "without moving the price", someone else sold 2.5% of the company... also without moving the price. So what you have is a matched trade with 1 buyer and 1 or more sellers. Once you understand how this works you can let go of conspiracy thoeries and "they" and it will feel much better. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
